Alex Jackson, PhD
Senior Director CMC
Alex holds a degree and PhD in Chemistry from the University of Warwick (Coventry, UK). In 2000 he joined Amersham Health (Amersham, UK) as a medicinal chemist. After Amersham Health was acquired by GE Healthcare, he gained experience in radiochemistry spanning early-phase discovery to late-stage development and cGMP manufacturing for clinical trials.
In 2020 Alex moved to Theragnostics Ltd. as the head of R&D, covering all aspects of CMC development and preparation for clinical trials, before joining Ariceum following its acquisition of Theragnostics.